Virax Biolabs Secures Exclusive SE Asia Supply Deal for ImmuneSelect with Fosun Diagnostics
VRAX•Virax Biolabs’ UK subsidiary signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling products across six Southeast Asian markets, establishing a purchase-order framework for immediate deliveries. The deal supports near-term revenue opportunities and paves the way for phased regional expansion and potential OEM arrangements.
1. Agreement Details
Virax Biolabs (UK) Limited has entered an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The framework sets minimum purchase and performance requirements and enables immediate product supply under purchase orders for ImmuneSelect immune profiling reagents.
2. Market Expansion
The agreement provides Virax with access to Fosun Diagnostics’ established regional commercial infrastructure, leveraging its customer network across six Southeast Asian markets. Initial commercial execution will focus on tuberculosis-related research applications in Thailand, with planned rollouts into additional markets based on demand.
3. Product Overview
ImmuneSelect is Virax’s research-use-only immune profiling product line, including ELISpot assay plates that measure cellular immune responses. This platform is distinct from ViraxImmune, the company’s in-development diagnostic platform undergoing clinical and regulatory development.
4. Growth Opportunities
The supply framework supports phased expansion into additional Virax products, higher-volume supply arrangements and potential OEM or private-label partnerships. Structured volume-based pricing tiers offer scalable economics across the ASEAN region, enhancing long-term commercial potential.
